Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 6, 2008, Pages 3309-3320

  Shimada, Itsuro ^a   Maeno, Kyoichi ^a   Kondoh, Yutaka ^a   Kaku, Hidetaka ^a   Sugasawa, Keizo ^a   Kimura, Yasuharu ^a   Hatanaka, Ken ichi ^a   Naitou, Yuki ^a   Wanibuchi, Fumikazu ^a   Sakamoto, Shuichi ^a   Tsukamoto, Shin ichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

5 HT2C receptor agonist; Benzazepine; Binding affinity; YM348

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE 7 CARBONITRILE; 6 CHLORO 3 METHYL 7 NITRO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 6 CHLORO 7 FLUORO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 6 CHLORO 7 METHOXY 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 6 CHLORO 7 NITRO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 6 CHLORO N METHYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 AMINE; 6,7 DICHLORO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 7 BROMO 6 CHLORO 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 7,8,9,10 TETRAHYDRO 6H FURO[2,3 G][3]BENZAZEPINE; 7,8,9,10 TETRAHYDRO 6H FURO[3,2 G][3]BENZAZEPINE; BENZAZEPINE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; VOLINANSERIN; YM 348;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; NONHUMAN; PENIS ERECTION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAZEPINES; CARDIOVASCULAR SYSTEM; PENILE ERECTION; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 40949086801     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.12.009     Document Type: Article

References (20)

1. Isaac M. Drugs Future 26 (2001) 383
2. Roth B.L., and Shapiro D.A. Exp. Opin. Ther. Targets 5 (2001) 685
3. Bishop M.J., and Nilsson B.M. Exp. Opin. Ther. Patents 13 (2003) 1691
4. Sargent P.A., Sharpley A.L., Williams C., Goodall E.M., and Cowen P.J. Psychopharmacology 133 (1997) 309
5. Vickers S.P., Easton N., Webster L.J., Wyatt A., Bickerdike M.J., Dourish C.T., and Kennett G.A. Psychopharmacology 167 (2003) 274
6. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., and Blackburn T.P. Neuropharmacology 36 (1997) 609
7. Martin J.R., Bos M., Jenck F., Moreau J.-L., Mutel V., Sleight A.J., Wichman J., Andrews J.S., Berendsen H.H.G., Broekkamp C.L.E., Ruigt G.S.F., Kohler C., and van Delft A.M.L. J. Pharmacol. Exp. Ther. 286 (1998) 913
8. Welmaker G.S., Nelson J.A., Sabalski J.E., Sabb A.L., Potoski J.R., Graziano D., Kagan M., Coupet J., Dunlop J., Mazandarani H., Rosenzweig-Lipson S., Sukoff S., and Zhang Y. Bioorg. Med. Chem. Lett. 10 (2000) 1991
9. Hayashi A., Sonoda R., Kimura Y., Takasu T., Suzuki M., Sasamata M., and Miyata K. Brain Res. 1011 (2004) 1991
10. Bentley J.M., Adams D.R., Bebbington D., Benwell K.R., Bickerdike M.J., Davidson J.E.P., Dawson C.E., Dourish C.T., Duncton M.A.J., Gaur S., George A.R., Giles P.R., Hamlyn R.J., Kennett G.A., Knight A.R., Malcolm C.S., Mansell H.L., Misra A., Monck N.J.T., Pratt R.M., Quirk K., Roffey J.R.A., Vickers S.P., and Cliffe I.A. Bioorg. Med. Chem. Lett. 14 (2004) 2367
11. Kimura Y., Hatanaka K., Naitou Y., Maeno K., Shimada I., Koakutsu A., Wanibuchi F., and Yamaguchi T. Eur. J. Pharmacol. 483 (2004) 37
12. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., Van Giersbergen P.L.M., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., and Widmaier C. J. Pharmacol. Exp. Ther. 277 (1996) 968
13. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., Sun J.H., Link J.R., Abbaszade I., Hollis J.M., Largent B.L., Hartig P.R., Hollis G.F., Meunier P.C., Robichaud A.J., and Robertson D.W. Mol. Pharmacol. 57 (2000) 75
14. Shimada I., Maeno K., Kazuta K., Kubota H., Kimizuka T., Kimura Y., Hatanaka K., Naitou Y., Wanibuchi F., Sakamoto S., and Tsukamoto S. Bioorg. Med. Chem. 16 (2008) 1966
15. Berendsen H.H.G., Jenck F., and Broekkamp C.L. Psychopharmacology 101 (1990) 57
16. Pazos A., Hoyer D., and Palacios J.M. Eur. J. Pharmacol. 106 (1985) 539
17. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. J. Biol. Chem. 193 (1951) 265
18. Cheng Y.C., and Prussoff W.H. Biochem. Pharmacol. 22 (1973) 3099
19. Aramori I., and Nakanishi S. Neuron 8 (1992) 757
20. Berendsen H.H.G., and Gower A.J. Neuroendocrinology 42 (1986) 185